News
ALPMF
10.80
NaN%
--
Weekly Report: what happened at ALPMF last week (1027-1031)?
Weekly Report · 4d ago
Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window
Seeking Alpha · 6d ago
Bicycle downgraded at RBC on pipeline delays
Seeking Alpha · 6d ago
Astellas Pharma gives H1 results
Seeking Alpha · 10/30 11:43
Astellas Pharma Revises FY2025 Financial Forecasts Upward
TipRanks · 10/30 07:07
Astellas Pharma’s ASP4396 Study: A Potential Game-Changer for Solid Tumors
TipRanks · 10/27 23:41
Astellas Pharma’s ASP3021 Study: A New Hope for AMD Patients?
TipRanks · 10/27 23:16
Astellas Pharma’s Peficitinib Study: Key Insights for Investors
TipRanks · 10/27 22:36
Astellas Pharma’s Innovative Bladder Device: A Game Changer in Urinary Health?
TipRanks · 10/27 21:33
Astellas Pharma’s Promising Phase 1 Study on ASP3082 for Advanced Solid Tumors
TipRanks · 10/27 21:08
Astellas Pharma’s ASP5834 Study: A New Hope for KRAS Mutation Cancers
TipRanks · 10/27 20:40
Pfizer and Astellas Study on Prostate Cancer Treatment: Key Insights for Investors
TipRanks · 10/27 19:35
Astellas Pharma’s Promising Prostate Cancer Study: A Market Game Changer?
TipRanks · 10/27 17:10
Weekly Report: what happened at ALPMF last week (1020-1024)?
Weekly Report · 10/27 10:00
Merck Keytruda formulations undergo FDA priority review for bladder cancer
Seeking Alpha · 10/23 12:23
Weekly Report: what happened at ALPMF last week (1013-1017)?
Weekly Report · 10/20 09:58
Why Is Taysha Gene Therapies Stock Falling Friday?
Benzinga · 10/17 16:44
I-Mab Biopharma Stock: Caution Warranted After Huge Surge
Seeking Alpha · 10/14 22:15
Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study
Barchart · 10/14 18:58
More
Webull provides a variety of real-time ALPMF stock news. You can receive the latest news about Astellas Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ALPMF
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.